KALY Beats 52wk High on News! via OTC PR WIRE
Post# of 103017
(Total Views: 142)
Posted On: 10/29/2018 11:45:26 AM
KALY Beats 52wk High on News!
via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products. Kali recently announced a letter of intent to acquire NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." Separately, Puration has licensed the NCM patent for use in specific commercial applications. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the joint venture, Kali would build on NCM's medical research, and Puration's commercial experience, combined with Nouveau's plans to develop a proprietary pharmaceutical grade hemp cultivar, to together develop cannabis pharmaceutical products in partnerships with established pharmaceutical development companies.
Frederick Ferri, CEO and Founder of NCM Biotech notes, "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products."
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Learn more about NCM Biotech at https://www.ncmbiotech.com/
Look for more info on Kali's plans with NCM Biotech and Puration and Nouveau later this week in a management presentation on the company's comprehensive post acquisition business plan.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"
, and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
via OTC PR WIRE -- Kali, Inc. (USOTC: KALY) today announced entering into discussions with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to explore forming a joint venture company between the three to develop cannabis pharmaceutical products. Kali recently announced a letter of intent to acquire NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." Separately, Puration has licensed the NCM patent for use in specific commercial applications. Nouveau has recently acquired a cannabis cultivation operation from Puration. In the joint venture, Kali would build on NCM's medical research, and Puration's commercial experience, combined with Nouveau's plans to develop a proprietary pharmaceutical grade hemp cultivar, to together develop cannabis pharmaceutical products in partnerships with established pharmaceutical development companies.
Frederick Ferri, CEO and Founder of NCM Biotech notes, "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products."
NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Learn more about NCM Biotech at https://www.ncmbiotech.com/
Look for more info on Kali's plans with NCM Biotech and Puration and Nouveau later this week in a management presentation on the company's comprehensive post acquisition business plan.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"
, and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors. CONTACT:
(1)
(0)Scroll down for more posts ▼